Lung transplantation: Current status and challenges

Transplantation

Volumn 81, Issue 12, 2006, Pages 1609-1615

  Pierson III, Richard N ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Division of Cardiac Surgery   (United States)

Author keywords

Acute Lung injury; Bronchiolitis obliterans syndrome; Chronic rejection; Lung allocation; Lung transplant; Reperfusion injury

Indexed keywords

ANTIFUNGAL AGENT; AZITHROMYCIN; FINGOLIMOD; GANCICLOVIR;

ACUTE LUNG INJURY; BRONCHIOLITIS OBLITERANS; CADAVER DONOR; CHRONIC GRAFT REJECTION; DEMOGRAPHY; EXTRACORPOREAL OXYGENATION; GRAFT DYSFUNCTION; HUMAN; LUNG FUNCTION; LUNG GAS EXCHANGE; LUNG INSUFFICIENCY; LUNG PERFUSION; LUNG TRANSPLANTATION; LUNG VENTILATION; ORGAN DONOR; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; REPERFUSION INJURY; RESOURCE ALLOCATION; REVIEW; TREATMENT INDICATION; XENOTRANSPLANTATION;

ANIMALS; GRAFT SURVIVAL; HUMANS; LUNG TRANSPLANTATION; TISSUE DONORS; TREATMENT OUTCOME;

EID: 33745444023     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000226058.05831.e5     Document Type: Review

References (129)

1. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306(10): 557.
2. Cooper JD, Pearson FG, Patterson GA, et al. Technique of successful lung transplantation in humans. J Thorac Cardiovasc Surg 1987; 93(2): 173.
3. Hardy JD, Alican F. Lung transplantation. Adv Surg 1966; 2: 235.
4. Veith FJ, Koerner SK, Hagstrom JW, et al. Experience in clinical lung transplantation. JAMA 1972; 222(7): 779.
5. Nelems JM, Rebuck AS, Cooper JD, et al. Human lung transplantation. Chest 1980; 78(4): 569.
6. Lima O, Cooper JD, Peters WJ, et al. Effects of methylprednisolone and azathioprine on bronchial healing following lung autotransplantation. J Thorac Cardiovasc Surg 1981; 82(2): 211.
7. Reitz BA, Bieber CP, Raney AA, et al. Orthotopic heart and combined heart and lung transplantation with cyclosporin-A immune suppression. Transplant Proc 1981; 13(1 Pt 1): 393.
8. Grillo HC. Surgical approaches to the trachea. Surg Gynecol Obstet 1969; 129(2): 347.
9. Blumenstock DA, Cannon FD. Prolonged survival of lung allografts in nonidentical beagles by treatment with lethal total-body irradiation, autologous bone marrow transplantation, and methotrexate. Transplantation 1978; 26(3): 203.
10. Reitz BA, Burton NA, Jamieson SW, et al. Heart and lung transplantation: autotransplantation and allotransplantation in primates with extended survival. J Thorac Cardiovasc Surg 1980; 80(3): 360.
11. Norin AJ, Veith FJ, Emeson EE, et al. Improved survival of transplanted lungs in mongrel dogs treated with cyclosporin A. Transplantation 1981; 32(3): 259.
12. Reitz BA, Gaudiani VA, Hunt SA, et al. Diagnosis and treatment of allograft rejection in heart-lung transplant recipients. J Thorac Cardiovasc Surg 1983; 85(3): 354.
13. Pierson RN 3rd, Barr ML, McCullough KP, et al. Thoracic organ transplantation. Am J Transplant 2004; 4(Suppl 9): 93.
14. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 2005; 24(8): 956.
15. Schroder C, Scholl F, Daon E, et al. A modified bronchial anastomosis technique for lung transplantation. Ann Thorac Surg 2003; 75(6): 1697.
16. Garfein ES, Ginsberg ME, Gorenstein L, McGregor CC, Schulman LL. Superiority of end-to-end versus telescoped bronchial anastomosis in single lung transplantation for pulmonary emphysema. J Thorac Cardiovasc Surg 2001; 121(1): 149.
17. Griffith BP, Magee MJ, Gonzalez IF, et al. Anastomotic pitfalls in lung transplantation. J Thorac Cardiovasc Surg 1994; 107(3): 743.
18. Anderson MB, Kriett JM, Harrell J, et al. Techniques for bronchial anastomosis. J Heart Lung Transplant 1995; 14(6 Pt 1): 1090.
19. Aigner C, Jaksch P, Seebacher G, et al. Single running suture-the new standard technique for bronchial anastomoses in lung transplantation. Eur J Cardiothorac Surg 2003; 23(4): 488.
20. Norgaard MA, Andersen CB, Pettersson G. Does bronchial artery revascularization influence results concerning bronchiolitis obliterans syndrome and/or obliterative bronchiolitis after lung transplantation? Eur J Cardiothorac Surg 1998; 14(3): 311.
21. Baudet EM, Dromer C, Dubrez J, et al. Intermediate-term results after en bloc double-lung transplantation with bronchial arterial revascularization. Bordeaux Lung and Heart-Lung Transplant Group. J Thorac Cardiovasc Surg 1996; 112(5): 1292.
22. Taghavi S, Birsan T, Seitelberger R, et al. Initial experience with two sequential anterolateral thoracotomies for bilateral lung transplantation. Ann Thorac Surg 1999; 67(5): 1440.
23. al-Kattan K, Tadjkarimi S, Cox A, et al. Evaluation of the long-term results of single lung versus heart-lung transplantation for emphysema. J Heart Lung Transplant 1995; 14(5): 824.
24. Stoica SC, McNeil KD, Perreas K, et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 2001; 72(6): 1887.
25. Appel JZ III, Davis RD. The evolution of lung transplantation: A clinical update. Transplant Rev 2004; 18: 20.
26. Fischer S, Meyer K, Tessmann R, et al. Outcome following single vs bilateral lung transplantation in recipients 60 years of age and older. Transplant Proc 2005; 37(2): 1369.
27. Egan TM. Ethical issues in thoracic organ distribution for transplant. Am J Transplant 2003; 3(4): 366.
28. Starnes VA, Bowdish ME, Woo MS, et al. A decade of living lobar lung transplantation: recipient outcomes. J Thorac Cardiovasc Surg 2004; 127(1): 114.
29. Date H, Tanimoto Y, Goto K, et al. A new treatment strategy for advanced idiopathic interstitial pneumonia: living-donor lobar lung transplantation. Chest 2005; 128(3): 1364.
30. Bowdish ME, Barr ML, Schenkel FA, et al. A decade of living lobar lung transplantation: perioperative complications after 253 donor lobectomies. Am J Transplant 2004; 4(8): 1283.
31. Novick RJ, Stitt LW, Al-Kattan K, et al. Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry. Ann Thorac Surg 1998; 65(1): 227.
32. Brugiere O, Thabut G, Castier Y, et al. Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients. Chest 2003; 123(6): 1832.
33. de Perrot M, Keshavjee S. Lung preservation. Semin Thorac Cardiovasc Surg 2004; 16(4): 300.
34. de Perrot M, Snell GI, Babcock WD, et al. Strategies to optimize the use of currently available lung donors. J Heart Lung Transplant 2004; 23(10): 1127.
35. Steen S, Liao Q, Wierup PN, et al. Transplantation of lungs from non-heart-beating donors after functional assessment ex vivo. Ann Thorac Surg 2003; 76(1): 244.
36. Van Raemdonck DE, Rega FR, Neyrinck AP, et al. Non-heart-beating donors. Semin Thorac Cardiovasc Surg 2004; 16(4): 309.
37. Loehe F, Preissler G, Annecke T, et al. Continuous infusion of nitroglycerin improves pulmonary graft function of non-heart-beating donor lungs. Transplantation 2004; 77(12): 1803.
38. Rega FR, Jannis NC, Verleden GM, et al. Should we ventilate or cool the pulmonary graft inside the non-heart-beating donor? J Heart Lung Transplant. 2003; 22(11): 1226.
39. Egan TM, Thomas Y, Gibson D, et al. Trigger for intercellular adhesion molecule-1 expression in rat lungs transplanted from non-heart-beating donors. Ann Thorac Surg 2004; 77(3): 1048.
40. Barr ML, Bourge RC, Orens JB, et al. Thoracic organ transplantation in the United States, 1994-2003. Am J Transplant 2005; 5(4 Pt 2): 934.
41. Pierson RN, Milstone AP, Loyd JE, et al. Lung allocation in the United States, 1995-1997: an analysis of equity and utility. J Heart Lung Transplant 2000; 19(9): 846.
42. Smits JM, Mertens BJ, Van Houwelingen HC, et al. Predictors of lung transplant survival in Eurotransplant. Am J Transplant 2003; 3(11): 1400.
43. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167(4): 490.
44. Meyers BF, de la Morena M, Sweet SC, et al. Primary graft dysfunction and other selected complications of lung transplantation: A single-center experience of 983 patients. J Thorac Cardiovasc Surg 2005; 129(6): 1421.
45. Thabut G, Vinatier I, Stern JB, et al. Primary graft failure following lung transplantation: predictive factors of mortality. Chest 2002; 121(6): 1876.
46. Parekh K, Meyer BF. Primary lung allograft dysfunction: a clinical and experimental review. Transplant Reviews 2005; 19: 88.
47. Sekine Y, Waddell TK, Matte-Martyn A, et al. Risk quantification of early outcome after lung transplantation: donor, recipient, operative, and post-transplant parameters. J Heart Lung Transplant 2004; 23(1): 96.
48. Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary transplantation: the role of brain death in donor lung injury. Transplantation 2003; 75(12): 1928.
49. Venuta F, Rendina EA, Bufi M, et al. Preimplantation retrograde pneumoplegia in clinical lung transplantation. J Thorac Cardiovasc Surg 1999; 118(1): 107.
50. Wittwer T, Franke U, Fehrenbach A, et al. Impact of retrograde graft preservation in Perfadex-based experimental lung transplantation. J Surg Res 2004; 117(2): 239.
51. Ardehali A, Laks H, Russell H, et al. Modified reperfusion and ischemia-reperfusion injury in human lung transplantation. J Thorac Cardiovasc Surg 2003; 126(6): 1929.
52. Glassman LR, Keenan RJ, Fabrizio MC, et al. Extracorporeal membrane oxygenation as an adjunct treatment for primary graft failure in adult lung transplant recipients. J Thorac Cardiovasc Surg 1995; 110(3): 723.
53. Meyers BF, Sundt TM 3rd, Henry S, et al. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg 2000; 120(1): 20.
54. Oto T, Rosenfeldt F, Rowland M, et al. Extracorporeal membrane oxygenation after lung transplantation: evolving technique improves outcomes. Ann Thorac Surg 2004; 78(4): 1230.
55. Dahlberg PS, Prekker ME, Herrington CS, et al. Medium-term results of extracorporeal membrane oxygenation for severe acute lung injury after lung transplantation. J Heart Lung Transplant 2004; 23(8): 979.
56. Gunther A, Walmrath D, Grimminger F, Seeger W. Pathophysiology of acute lung injury. Semin Respir Crit Care Med 2001; 22(3): 247.
57. Tzouvelekis A, Pneumatikos I, Bouros D. Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator. Respir Res 2005; 6(1): 62.
58. Toy P, Popovsky MA, Abraham E, et al. National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33(4): 721.
59. Dreyfuss D, Ricard JD. Acute lung injury and bacterial infection. Clin Chest Med. 2005; 26(1): 105.
60. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005; 23: 821.
61. Puneet P, Moochhala S, Bhatia M. Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2005; 288(1): L3.
62. Grigoryev DN, Finigan JH, Hassoun P, Garcia JG. Science review: searching for gene candidates in acute lung injury. Crit Care 2004; 8(6): 440.
63. McVerry BJ, Garcia JGN. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem 2004; 92: 1075.
64. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005; 280(17): 17286.
65. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344(10): 699.
66. Seibert AF, Thompson WJ, Taylor A, et al. Reversal of increased microvascular permeability associated with ischemia-reperfusion: role of cAMP. J Applied Physiol 1992; 72(1): 389.
67. Khimenko PL, Moore TM, Hill LW, et al. Adenosine A2 receptors reverse ischemia-reperfusion lung injury independent of beta-receptors. J Appl Physiol 1995; 78(3): 990.
68. Keshavjee S, Davis RD, Zamora MR, et al. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg 2005; 129(2): 423.
69. Itano H, Mora BN, Zhang W, et al. Lipid-mediated ex vivo gene transfer of viral interleukin 10 in rat lung allotransplantation. J Thorac Cardiovasc Surg 2001; 122(1): 29.
70. Martins S, de Perrot M, Imai Y, et al. Transbronchial administration of adenoviral-mediated interleukin-10 gene to the donor improves function in a pig lung transplant model. Gene Ther 2004; 11(24): 1786..
71. Maurer JR, Frost AE, Estenne M, et al. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 1998; 66(7): 951.
72. Patel VS, Palmer SM, Messier RH, Davis RD. Clinical outcome after coronary artery revascularization and lung transplantation. Ann Thorac Surg 2003; 75(2): 372.
73. Martinez FJ, Kotloff R. Prognostication in chronic obstructive pulmonary disease: implications for lung transplantation. Semin Respir Crit Care Med 2001; 22(5): 489.
74. Egan TM, Bennett LE, Garrity ER, et al. Predictors of death on the UNOS lung transplant waiting list: results of a multivariate analysis. J Heart Lung Transplant 2001; 20(2): 242.
75. Martinez FJ, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26(2): 167.
76. Groen H, van der Bij W, Koeter GH, TenVergert EM. Cost-effectiveness of lung transplantation in relation to type of end-stage pulmonary disease. Am J Transplant 2004; 4(7): 1155.
77. Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001; 20(5): 511.
78. Bhorade SM, Jordan A, Villanueva J, et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. Am J Transplant 2003; 3(12): 1570.
79. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60(3): 580.
80. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 2004; 23(1): 159.
81. Palmer SM, Baz MA, Sanders L, et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention ot acute lung allograft rejection. Transplantation 2001; 71(12): 1772.
82. Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 2003; 125(4): 891.
83. Snell GI, Lewey BJ, Zheng L, et al. Everolimus alters the bronchoalveolar lavage and endobronchial biopsy immunologic profile post-human lung transplantation. Am J Transplant 2005; 5(6): 1446.
84. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75(9): 1437.
85. Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant. 2004; 23(5): 632.
86. Garrity ER Jr., Villanueva J, Bhorade SM, et al. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001; 71(6): 773.
87. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005; 130(2): 528.
88. Iacono AT, Corcoran TE, Griffith BP, et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J. 2004; 23(3): 384.
89. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005; 79(11): 1553.
90. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353(8): 770.
91. Pierson RN 3rd, Crowe JE Jr., Pfeiffer S, et al. CD40-ligand in primate cardiac allograft and viral immunity. Immunol Res 2001; 23(2-3): 253.
92. Hancock WW. Chemokine receptor-dependent alloresponses. Immunol Rev 2003; 196: 37.
93. Nguyen BN, Schroeder C, Zhang T, et al. CCR5 blockade attenuates inflammation and cardiac allograft vasculopathy in non-human primates treated with cyclosporine A. J Heart Lung Transplant 2006; 2: 578.
94. Brumble LM, Milstone AP, Loyd JE, et al. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir. Chest 2002; 121(2): 407.
95. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15(1 Pt 1): 1.
96. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12(5): 713.
97. Verleden GM, Dupont LJ, Van Raemdonck DE. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal? Eur Respir J 2005; 25(2): 221.
98. Cantu E 3rd, Appel JZ 3rd, Hartwig MG, et al. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78(4): 1142.
99. Davis RD Jr., Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125(3): 533.
100. Shoji T, Wain JC, Houser SL, et al. Indirect recognition of MHC class I allopeptides accelerates lung allograft rejection in miniature swine. Am J Transplant 2005; 5(7): 1626.
101. Khalifah AP, Hachem RR, Chakinala MM, et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005; 5(8): 2022.
102. Jaramillo A, Fernandez FG, Kuo EY, et al. Immune mechanisms in the pathogenesis of bronchiolitis obliterans syndrome after lung transplantation. Pediatr Transplant 2005; 9(1): 84.
103. Hadjiliadis D, Chaparro C, Reinsmoen NL, et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005; 24: S249.
104. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004; 286(6): L1129.
105. Jackson A, Palmer S, Davis RD, et al. Cytokine genotypes in kidney, heart, and lung recipients: consequences for acute and chronic rejection. Transplant Proc 2001; 33(1-2): 489.
106. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168(6): 628.
107. Christie JD, Kotloff RM, Ahya VN, et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171(11): 1312.
108. Nelsestuen GL, Martinez MB, Hertz MI, et al. Proteomic identification of human neutrophil alpha-defensins in chronic lung allograft rejection. Proteomics 2005; 5(6): 1705.
109. Bowdish ME, Arcasoy SM, Wilt JS, et al. Surrogate markers and risk factors for chronic lung allograft dysfunction. Am J Transplant 2004; 4(7): 1171.
110. Shitrit D, Bendayan D, Gidon S, et al. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005; 24(9): 1440.
111. Gao SZ, Chaparro SV, Perlroth M, et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003; 22(5): 505.
112. Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124(4): 1242.
113. Smith JD, Danskine AJ, Laylor RM, et al. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol 1993; 1(1): 60.
114. Hadjiliadis D, Chaparro C, Reinsmoen NL, et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005; 24(7): S249.
115. Magro CM, Klinger DM, Adams PW, et al. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant 2003; 3(10): 1264.
116. Ramachandran S, Goers T, Parekh K, et al. Epithelial specific, non-MHC antibodies, induce hyperacute rejection of human lung allografts. Presented at American Society for Histocompatibility and Immunogenetics, Washington, D.C., November 2005.
117. Resnick D. The Jesica Santillan tragedy: lessons learned. Hastings Cent Rep 2003; 33(4): 15.
118. Transplant News, March 9, 2004; p7.
119. Pierson RN 3rd, Loyd JE, Goodwin A, et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation 2002; 74(1): 79.
120. Banner NR, Rose ML, Cummins D, et al. Management of an ABO-incompatible lung transplant. Am J Transplant 2004; 4(7): 1192.
121. Choong CK, Meyers BF. Quality of life after lung transplantation. Thorac Surg Clin 2004; 14(3): 385.
122. Singer LG. Cost-effectiveness and quality of life: benefits of lung transplantation. Respir Care Clin N Am 2004; 10(4): 449.
123. Nguyen BH, Zwets E, Schroeder C, et al. Beyond antibody-mediated rejection: hyperacute lung rejection as a paradigm for dysregulated inflammation. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5(3): 255.
124. Lau CL, Cantu E 3rd, Gonzalez-Stawinski GV, et al. The role of antibodies and von Willebrand factor in discordant pulmonary xenotransplantation. Am J Transplant 2003; 3(9): 1065.
125. Collins BJ, Blum MG, Parker RE, et al. Thromboxane mediates pulmonary hypertension and lung inflammation during hyperacute lung rejection. J Appl Physiol. 2001; 90(6): 2257.
126. Massicot-Fisher J, Noel P, Madsen JC. Recommendations of the National Heart, Lung and Blood Institute Heart and Lung Tolerance Working Group. Transplantation 2001; 72(8): 1467.
127. Azimzadeh AM, Pfeiffer S, Wu GS, et al. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant. 2005; 5(10): 2349.
128. Wu ZJ, Gartner M, Litwak KN, Griffith BP. Progress toward an ambulatory pump-lung. J Thorac Cardiovasc Surg 2005; 130(4): 973.
129. Bartlett RH. Extracorporeal life support: history and new directions. Semin Perinatol 2005; 29(1): 2.